Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report

Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report

Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with a dismal prognosis. Atezolizumab plus bevacizumab (atezo-bev) is the recommended palliative treatment, and approximately 10% of the patients may experience a complete response (CR), according to the mRECIST cr...

Full description

Saved in:
Bibliographic Details
Main Authors: Pramod Kumar, Pradeep Krishna, Rohit Maidur, Naveen Chandrashekhar, Suresh Raghavaiah
Format: Article
Language:English
Published: Korean Liver Cancer Association 2025-03-01
Series:Journal of Liver Cancer
Subjects:
liver cirrhosis
carcinoma, hepatocellular
immunotherapy
liver transplantation
hepatitis c
Online Access:http://e-jlc.org/upload/pdf/jlc-2024-09-26.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://e-jlc.org/upload/pdf/jlc-2024-09-26.pdf

Similar Items